J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vashi, V.
Right arrow Articles by Phillips, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vashi, V.
Right arrow Articles by Phillips, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Pharmacokinetic Interaction between Finasteride and Terazosin, but not Finasteride and Doxazosin

Vijay Vashi, PhD

Menger Chung, PhD, FCP

James Hilbert, PhD

Victor Lawrence, MD

Kem Phillips, PhD

Central Research Division, Pfizer, Inc., New York, New York

The {alpha}1-adrenoceptor antagonists doxazosin and terazosin and the 5{alpha}-reductase inhibitor finasteride are used in the treatment of benign prostatic hyperplasia. The aim of this study was to assess the potential pharmacokinetic inteaction of doxazosin or terazosin when coadministered with finasteride. This was a randomized, placebo-cotrolled, multi-center study. Ninety healthy men were assigned to one of six treatment groups: doxazosin; doxazsin plus finasteride; terazosin; terazosin plus finasteride; placebo; and placebo plus finasteride. Plasma concentrations, maximum plasma concentration (Cmax), time to maximum concentration (tmax), and area under the plasma concentration-time curve from 0 to 24 hours (A UC0-24) of doxazosin, terazosin, and finasteride were determined. Ratios of Cinax and AUC for doxazosin and terazosin were not significantly altered by coadministration with finasteride. The Cmax and AUCO0-24 of finasteride were not significantly altered by coadministration with doxazosin. However, Cmax and AUC0-24 of finasteride were significantly higher after coadministration with terazosin. There is no statistically significant pharmacokinetic interaction between finasteride and doxazosin; however, there is a statistically significant interaction between finasteride and terazosin, which affects the pharmacokinetics of fiasteride but not those of terazosin. The clinical significance of this interaction remains to be determined.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Clinical Pharmacology